07/22/2026
https://www.facebook.com/share/1JcjfCD1aN/?mibextid=wwXIfr
STRONGER DEFENSE: An experimental pancreatic cancer vaccine triggers immune response in 90% of high-risk patients in Johns Hopkins trial.
The vaccine, called mKRAS-VAX, targets the gene mutation that drives more than 90% of the deadliest form of pancreatic cancer — and after 16.5 months of follow-up, no participant developed the disease.
Some pancreatic cysts shrank or disappeared in over a third of vaccinated individuals, though researchers say larger studies are needed to confirm the vaccine caused the effect.
➡ Full story here: https://www.foxnews.com/health/pancreatic-cancer-vaccine-shows-promise-first-human-trial-preventing-disease-high-risk-patients